|
Activity Number:
|
460
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Wednesday, August 5, 2009 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biometrics Section
|
| Abstract - #305699 |
|
Title:
|
Biomarker and Clinical Endpoint in Asthma
|
|
Author(s):
|
Yun Chon*+
|
|
Companies:
|
Amgen, Inc.
|
|
Address:
|
One Amgen Center Dr. MS 24-2-C, Thousand Oaks, CA, 91320,
|
|
Keywords:
|
Biomarker ; Astham ; Asthma Control Questionnaire
|
|
Abstract:
|
The goal of therapeutic target in asthma is to reduce the burden of the disease that a patient experiences and is represented as a clinical endpoint such as Asthma Control Questionnaire (ACQ). An objectively quantifiable measure correlated with clinical manifestation of asthma can be a biomarker to detect the state of disease and its progression or response to treatment regimen. A broad range of biomarkers are associated with asthma, including level of inflammatory mediator, sputum composition, and measure of airway physiology. The use of a biomarker in clinical trials has been studied as a relationship with a clinical endpoint related to a specific disease pathway. This is a concern in asthma since patient experience clinical features that are contributed by a large number of biologic processes. This paper will investigate the relationship between ACQ and biomarkers in asthma.
|
- The address information is for the authors that have a + after their name.
- Authors who are presenting talks have a * after their name.
Back to the full JSM 2009 program |
